vs

Side-by-side financial comparison of Pioneer Bancorp, Inc. (PBFS) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

RECURSION PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($35.5M vs $25.0M, roughly 1.4× Pioneer Bancorp, Inc.). Pioneer Bancorp, Inc. runs the higher net margin — 82.1% vs -304.2%, a 386.3% gap on every dollar of revenue. Over the past eight quarters, Pioneer Bancorp, Inc.'s revenue compounded faster (144.9% CAGR vs 60.5%).

Pioneer Bancorp, Inc. (MD) is a bank holding company operating as the parent entity of Pioneer Bank. It provides a full suite of retail and commercial banking products and services, including deposit accounts, residential and commercial mortgages, consumer loans, and small business financing, primarily serving individual and corporate customers across local communities in Maryland, U.S.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

PBFS vs RXRX — Head-to-Head

Bigger by revenue
RXRX
RXRX
1.4× larger
RXRX
$35.5M
$25.0M
PBFS
Higher net margin
PBFS
PBFS
386.3% more per $
PBFS
82.1%
-304.2%
RXRX
Faster 2-yr revenue CAGR
PBFS
PBFS
Annualised
PBFS
144.9%
60.5%
RXRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
PBFS
PBFS
RXRX
RXRX
Revenue
$25.0M
$35.5M
Net Profit
$3.7M
$-108.1M
Gross Margin
59.8%
Operating Margin
21.3%
-304.8%
Net Margin
82.1%
-304.2%
Revenue YoY
681.7%
Net Profit YoY
39.6%
EPS (diluted)
$0.16
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PBFS
PBFS
RXRX
RXRX
Q4 25
$25.0M
$35.5M
Q3 25
$24.0M
$5.2M
Q2 25
$24.4M
$19.2M
Q1 25
$22.8M
$14.7M
Q4 24
$4.5M
Q3 24
$22.0M
$26.1M
Q2 24
$20.9M
$14.4M
Q1 24
$21.6M
$13.8M
Net Profit
PBFS
PBFS
RXRX
RXRX
Q4 25
$3.7M
$-108.1M
Q3 25
$4.3M
$-162.3M
Q2 25
$6.5M
$-171.9M
Q1 25
$5.8M
$-202.5M
Q4 24
$-178.9M
Q3 24
$6.3M
$-95.8M
Q2 24
$3.9M
$-97.5M
Q1 24
$4.7M
$-91.4M
Gross Margin
PBFS
PBFS
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
PBFS
PBFS
RXRX
RXRX
Q4 25
21.3%
-304.8%
Q3 25
23.4%
-3327.6%
Q2 25
33.3%
-916.8%
Q1 25
32.5%
-1297.9%
Q4 24
-4042.4%
Q3 24
37.2%
-377.1%
Q2 24
24.1%
-697.4%
Q1 24
28.1%
-698.4%
Net Margin
PBFS
PBFS
RXRX
RXRX
Q4 25
82.1%
-304.2%
Q3 25
18.0%
-3135.3%
Q2 25
26.4%
-894.2%
Q1 25
25.3%
-1373.3%
Q4 24
-3935.5%
Q3 24
28.7%
-367.5%
Q2 24
107.4%
-676.6%
Q1 24
21.9%
-662.4%
EPS (diluted)
PBFS
PBFS
RXRX
RXRX
Q4 25
$0.16
$-0.17
Q3 25
$0.18
$-0.36
Q2 25
$0.26
$-0.41
Q1 25
$0.23
$-0.50
Q4 24
$-0.56
Q3 24
$0.25
$-0.34
Q2 24
$0.15
$-0.40
Q1 24
$0.19
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PBFS
PBFS
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$323.9M
$1.1B
Total Assets
$2.2B
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PBFS
PBFS
RXRX
RXRX
Q4 25
$743.3M
Q3 25
$659.8M
Q2 25
$525.1M
Q1 25
$500.5M
Q4 24
$594.4M
Q3 24
$427.6M
Q2 24
$474.3M
Q1 24
$296.3M
Total Debt
PBFS
PBFS
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
PBFS
PBFS
RXRX
RXRX
Q4 25
$323.9M
$1.1B
Q3 25
$314.2M
$1.0B
Q2 25
$314.2M
$919.1M
Q1 25
$310.7M
$933.9M
Q4 24
$1.0B
Q3 24
$303.8M
$524.6M
Q2 24
$296.5M
$584.4M
Q1 24
$289.0M
$401.2M
Total Assets
PBFS
PBFS
RXRX
RXRX
Q4 25
$2.2B
$1.5B
Q3 25
$2.2B
$1.4B
Q2 25
$2.1B
$1.3B
Q1 25
$2.1B
$1.3B
Q4 24
$1.4B
Q3 24
$2.0B
$726.5M
Q2 24
$775.9M
Q1 24
$2.0B
$557.8M
Debt / Equity
PBFS
PBFS
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PBFS
PBFS
RXRX
RXRX
Operating Cash FlowLast quarter
$11.1M
$-46.1M
Free Cash FlowOCF − Capex
$-47.3M
FCF MarginFCF / Revenue
-133.1%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
2.97×
TTM Free Cash FlowTrailing 4 quarters
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PBFS
PBFS
RXRX
RXRX
Q4 25
$11.1M
$-46.1M
Q3 25
$3.9M
$-117.4M
Q2 25
$5.1M
$-76.4M
Q1 25
$-3.5M
$-132.0M
Q4 24
$-115.4M
Q3 24
$1.9M
$-59.2M
Q2 24
$9.0M
$-82.2M
Q1 24
$3.3M
$-102.3M
Free Cash Flow
PBFS
PBFS
RXRX
RXRX
Q4 25
$-47.3M
Q3 25
$-117.6M
Q2 25
$-79.6M
Q1 25
$-133.8M
Q4 24
$-116.7M
Q3 24
$-63.8M
Q2 24
$-83.4M
Q1 24
$-109.0M
FCF Margin
PBFS
PBFS
RXRX
RXRX
Q4 25
-133.1%
Q3 25
-2272.5%
Q2 25
-413.9%
Q1 25
-907.4%
Q4 24
-2567.7%
Q3 24
-244.6%
Q2 24
-578.5%
Q1 24
-789.9%
Capex Intensity
PBFS
PBFS
RXRX
RXRX
Q4 25
3.5%
Q3 25
4.7%
Q2 25
16.4%
Q1 25
12.4%
Q4 24
28.6%
Q3 24
17.5%
Q2 24
8.2%
Q1 24
48.2%
Cash Conversion
PBFS
PBFS
RXRX
RXRX
Q4 25
2.97×
Q3 25
0.90×
Q2 25
0.78×
Q1 25
-0.61×
Q4 24
Q3 24
0.30×
Q2 24
2.30×
Q1 24
0.70×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons